Testing a new drug for advanced cancers with gene changes
Part of Brain & nervous system, Cancer clinical trials.
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced breast, prostate, ovarian, or pancreatic cancer with a specific gene change.
- You have had at least one prior cancer treatment.
- You are able to take care of yourself (daily activities aren't limited).
- You haven't taken a PARP1-selective inhibitor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
This study tests an experimental pill (DAT-2645) for people with advanced or metastatic solid tumors that have DNA repair problems, such as BRCA gene mutations. The drug targets a repair mechanism that these cancer cells need, potentially slowing or stopping their growth.
This trial is testing a new drug called DM5167 for people whose advanced solid tumors have a BRCA1 or BRCA2 gene mutation. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests an experimental drug for people with advanced solid tumors or lymphoma that has not responded to standard treatments and has a specific genetic change (loss of MTAP or CDKN2A genes). The drug is taken by mouth and may work by targeting cancer cells with this change.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This study tests an experimental drug (DES-1357) for people with a specific type of advanced colorectal cancer that has not responded to previous treatments. The drug is designed to target tumors with a genetic mismatch repair deficiency, potentially helping to slow or stop cancer growth.
Hear when a new Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.